- Home
- QURE
QURE
uniQure N.V.
as 07-23-2025 12:41pm EST
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Upcoming Earnings Alert:
Get ready for potential market movements as uniQure N.V. QURE prepares to release earnings report on 29 Jul 2025.
| Founded: | 1998 | Country: | Netherlands |
| Employees: | N/A | City: | AMSTERDAM |
| Market Cap: | 725.4M | IPO Year: | 2007 |
| Target Price: | $37.20 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.45 - $19.18 | Next Earning Date: | 07-29-2025 |
| Revenue: | $20,201,000 | Revenue Growth: | 6.30% |
| Revenue Growth (this year): | -21.83% | Revenue Growth (next year): | 278.91% |
Stock Insider Trading Activity of uniQure N.V. (QURE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| POST LEONARD E | QURE | Director | Jun 20 '25 | Sell | $14.45 | 2,112 | $30,518.40 | 29,937 | |
| Kaye Jack | QURE | Director | Jun 20 '25 | Sell | $14.45 | 2,112 | $30,518.40 | 20,439 | |
| Meek David D. | QURE | Director | Jun 20 '25 | Sell | $14.45 | 2,112 | $30,518.40 | 34,190 | |
| Gut Robert | QURE | Director | Jun 20 '25 | Sell | $14.45 | 3,336 | $48,205.20 | 56,879 | |
| Springhorn Jeremy P. | QURE | Director | Jun 20 '25 | Sell | $14.45 | 2,112 | $30,518.40 | 37,694 | |
| Balachandran Madhavan | QURE | Director | Jun 20 '25 | Sell | $14.45 | 2,112 | $30,518.40 | 37,697 | |
| Potts Jeannette | QURE | Chief Legal Officer | Jun 16 '25 | Sell | $15.14 | 4,670 | $70,703.80 | 115,073 |
Latest uniQure N.V. News
QURE Breaking Stock News: Dive into QURE Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint
GlobeNewswire
a month ago
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
TipRanks
2 months ago
Lake Street says AMT-130 could be ‘significantly impactful’ for ClearPoint
MT Newswires
2 months ago
UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy
GlobeNewswire
2 months ago
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
GlobeNewswire
2 months ago
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
GlobeNewswire
2 months ago
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
Zacks
2 months ago
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?
Compare QURE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QURE uniQure N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.